Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1NET 1Endocrine 1CNS 1Breast 1

Conditions

Glioblastoma 2Neuroendocrine Tumors 1Neoplasms 1Gliosarcoma 1Brain Neoplasms 1

Interventions

Temozolomide 19Bevacizumab 14Irinotecan 12Carboplatin 10Cyclophosphamide 9Radiosurgery 8Lomustine 8Radiotherapy 7pembrolizumab 6Vincristine 6Topotecan 6Drug Therapy 6Surgical Procedures, Operative 5Etoposide 5Doxorubicin 5Cisplatin 53-Iodobenzylguanidine 5trametinib 4Metformin 4Gemcitabine 4Dexamethasone 4Blood Specimen Collection 4poly ICLC 3dabrafenib 3Vorinostat 3Trastuzumab 3Therapeutics 3Radiation 3Paclitaxel 3Observation 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neoplasms × dactolisib × CNS × Clear all
NCT01508104 2017-08-23

Safety Study of BEZ235 With Everolimus in Subjects With Advanced Solid Tumors

University of Cincinnati

Phase 1 Terminated
19 enrolled
CNSEndocrineNET

Brain Neoplasms, Glioblastoma, Neoplasms, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡